Health Care: Drugs

Seattle Genetics Inc (SGEN: NASDAQ)

$63.52 -0.95 | -1.47%
03/29/17 - 03:31 PM ET
Company Profile
Price and Volume
Recent Price 64.47
52 Week High 75.36
52 Week Low 32.40
Avg. Daily Vol. (Mil) 0.93
Beta (3 year) 2.51
Share Related Items
Mkt Cap (Mil) 9,186.57
Shares Out (Mil) 142.49
Float (Mil) 61.54
Dividend Information
Yield % 0.00
Annual Dividend 0.00
Payout Ratio 0.00
Financial Strength
Quick Ratio 4.40
Current Ratio 4.90
LT Debt/ Equity 0.00
Total Debt / Equity 0.00
Valuation Ratios
Price Earnings n.a.
Price/Sales 21.97
Price/Book 14.49
Price/Cash Flow -78.30
Per Share Data
Earnings -1.00
Sales 2.93
Book Value 4.45
Cash Flow -0.82
Business Summary
Seattle Genetics Inc is a biotechnology company. It develops & commercializes monoclonal antibody-based therapies for treating cancer. Its products ADCETRIS is used for treating relapsed Hodgkin lymphoma & relapsed systemic anaplastic large cell lymphoma.
General Information
21823 - 30th Drive S.E.
Building 3
Bothell, WA 98021
www.seattlegenetics.com
Industry : Drugs
Sector: Health Care
Employees: 890
CEO: Dr. Clay B. Siegall,PhD
Short Interest
Current Month (Mil) 10.28
Previous Month (Mil) 10.59
Short Interest Ratio (Days) 11.70
Management Effectiveness
Return on Equity n.a.
Return on Assets -16.70
Return on Investments -22.10
Profitability
Gross Margin 95.30
EBIT Margin -33.50
Profit Margin -33.50

Portfolios with SGEN

Latest SGEN Headlines from TheStreet

More Financial News for SGEN

Press Releases for SGEN

See All Press Releases
brokerage partners
watch thestreet tv
No Videos Found
connect with Stockpickr
Fan us on FaceBook
Follow us on Twitter